ReviewScience progress
Bridging pandemic and oncology challenges: Surface-enhanced Raman spectroscopy in the fight against COVID-19 and cancer.
Review in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While Raman spectroscopy itself stands on the principle of inelastic scattering of light, surface-enhanced Raman spectroscopy (SERS) amplifies those normally rather weak Raman signals by way of interactions between molecules and nanostructured metal surfaces. The technique has rapidly evolved into a very powerful analytical tool with enormous potential in combating cancer and COVID-19. SERS is a useful tool for diagnostics and treatment monitoring because of its remarkable sensitivity and ability to detect low-abundance molecules; nevertheless, standardizing techniques, guaranteeing reproducibility across several platforms, and overcoming problems related to signal enhancement and sensitivity under different experimental conditions remain challenges. SERS is also being explored about the COVID-19 pandemic, where its high sensitivity and specificity hold a promise in diagnostics, treatment monitoring, and even environmental tracing of the virus. When it comes to treatment, SERS-based theragnostic applications offer a two-pronged approach by combining therapeutic interventions with diagnostic capabilities that would make different therapies more accurate and effective. Approaches to SERS-guided drug delivery systems are discussed that would allow the drug to reach exactly where the antiviral agent is wanted, hence reducing side effects and enhancing treatment outcomes. Other approaches examined, including nanoparticle-based SERS for targeted therapy and the design of SERS tags, allow therapy and develop new ways of treatment against this virus. Finally, potential future developments of SERS technology and its wider applications in cancer and virology are discussed, with a specific view on the impact SERS might have on how infectious diseases are treated. In addition to discussing its present and potential uses, this narrative review emphasizes the critical role that SERS plays in developing and tracking cancer and COVID-19 treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.